Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 3/20 | 0.55 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.44 |
| ▸ | MET | P08581 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807229 | 0.86 | BRD4 (0.59) | P2RX7BRD4CREBBPMAPK1 | |
| SCHEMBL15084429 | 0.80 | BRD4 (0.48) | P2RX7BRD4CREBBPMAPK1 | |
| SCHEMBL807436 | 0.78 | BRD4 (0.60) | P2RX7BRD4CREBBPMAPK1MET | |
| SCHEMBL10801839 | 0.78 | MAPK1 (0.76) | P2RX7BRD4CREBBPMAPK1 | |
| SCHEMBL15064815 | 0.77 | BRD4 (0.58) | P2RX7BRD4CREBBPMAPK1 | |
| SCHEMBL17877244 | 0.77 | BRD4 (0.58) | P2RX7BRD4CREBBPMAPK1MET | |
| SCHEMBL807352 | 0.76 | MAPK1 (0.58) | P2RX7BRD4CREBBPMAPK1 | |
| SCHEMBL10210906 | 0.75 | MAPK1 (0.58) | BRD4CREBBPMAPK1 | |
| SCHEMBL15065745 | 0.74 | P2RX7 (0.54) | P2RX7BRD4CREBBPMAPK1MET | |
| SCHEMBL23841127 | 0.73 | BRD4 (0.63) | P2RX7BRD4CREBBPMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
| WO-2012036997-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | SCHERING CORPORATION (US) | 2012-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | P2RX7 2924/4885BRD4 845/4885CREBBP 183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.